Valuation : Armata Pharmaceuticals, Inc.

Market Cap 22Cr 19Cr 18Cr 16Cr 30Cr 2.05TCr 30Cr 208.25Cr 80Cr 1.05TCr 82Cr 80Cr 3.35TCr P/E 2026 *
-3.13x
P/E 2027 * -4.04x
Enterprise Value 22Cr 19Cr 18Cr 16Cr 30Cr 2.05TCr 30Cr 208.25Cr 80Cr 1.05TCr 82Cr 80Cr 3.35TCr EV / Sales 2026 *
51.1x
EV / Sales 2027 * 79x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day+5.80%
1 week+5.99%
Current month+5.99%
1 month+23.99%
3 months-22.13%
6 months-44.91%
Current year-7.01%
1 week 5.2
Extreme 5.2
5.86
1 month 3.96
Extreme 3.96
5.86
Current year 3.48
Extreme 3.48
14.98
1 year 2.79
Extreme 2.79
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+5.80%+5.99%+104.91%+90.85% 22Cr
-0.38%-0.99%+42.69%+100.85% 6.78TCr
-0.58%-2.39%+33.41%+78.46% 6.32TCr
-0.31%+3.67%-12.96%+374.95% 2.76TCr
+0.86%+2.12%-7.74%-13.34% 2.61TCr
+1.69%-0.36%+26.48%+15.46% 2.54TCr
+1.47%+1.26%+25.01%-17.50% 1.99TCr
+1.15%-5.02%+219.82%+379.02% 1.74TCr
-0.49%-0.37%-7.31%+524.84% 1.5TCr
-0.20%+8.00%+55.78%+167.98% 1.46TCr
Average +0.91%+2.38%+48.01%+170.16% 2.77TCr
Weighted average by Cap. +0.14%+0.91%+36.70%+139.84%

Financials

2026 *2027 *
Net sales 42.5L 36.55L 34.38L 31.38L 58.69L 40Cr 58.88L 4.08Cr 1.58Cr 21Cr 1.6Cr 1.56Cr 66Cr 27.5L 23.65L 22.24L 20.31L 37.98L 26Cr 38.1L 2.64Cr 1.02Cr 13Cr 1.03Cr 1.01Cr 42Cr
Net income -7.66Cr -6.59Cr -6.2Cr -5.66Cr -11Cr -724.44Cr -11Cr -73Cr -28Cr -370.98Cr -29Cr -28Cr -1.18TCr -7.2Cr -6.19Cr -5.82Cr -5.32Cr -9.94Cr -680.93Cr -9.97Cr -69Cr -27Cr -348.71Cr -27Cr -26Cr -1.11TCr
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
04/26/04 $5.840 +5.80% 48,032
03/26/03 $5.520 -0.18% 49,496
02/26/02 $5.530 +4.73% 70,066
01/26/01 $5.280 -4.17% 46,464
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.840USD
Average target price
17.50USD
Spread / Average Target
+199.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!